Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Total Non-Current Liabilities (2016 - 2025)

ImmunityBio (IBRX) has disclosed Total Non-Current Liabilities for 12 consecutive years, with $415.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 50.87% to $415.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $415.2 million, a 50.87% decrease, with the full-year FY2025 number at $415.2 million, down 50.87% from a year prior.
  • Total Non-Current Liabilities was $415.2 million for Q4 2025 at ImmunityBio, down from $928.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.1 billion in Q3 2024 to a low of $337.3 million in Q1 2022.
  • A 5-year average of $772.0 million and a median of $828.6 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: soared 150.62% in 2023, then tumbled 50.87% in 2025.
  • ImmunityBio's Total Non-Current Liabilities stood at $712.4 million in 2021, then grew by 14.0% to $812.2 million in 2022, then soared by 34.12% to $1.1 billion in 2023, then decreased by 22.43% to $844.9 million in 2024, then crashed by 50.87% to $415.2 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Total Non-Current Liabilities are $415.2 million (Q4 2025), $928.1 million (Q3 2025), and $971.2 million (Q2 2025).